Pierre Vanden Borre
Overview
Explore the profile of Pierre Vanden Borre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kasi P, Lee J, Pasquina L, Decker B, Vanden Borre P, Pavlick D, et al.
Clin Cancer Res
. 2023 Dec;
30(4):836-848.
PMID: 38060240
Purpose: Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor suppressor genes. This study examines the landscape of fusions and rearrangements detected by liquid biopsy (LBx) of circulating tumor...
2.
Reitsma M, Fox J, Vanden Borre P, Cavanaugh M, Chudnovsky Y, Erlich R, et al.
J Manag Care Spec Pharm
. 2019 Jan;
25(5):601-611.
PMID: 30632889
Background: Comprehensive genomic profiling (CGP) is a next-generation sequencing-based methodology that detects 4 classes of genomic alterations, as well as gene signature biomarkers such as microsatellite instability and tumor mutational...
3.
Pozdeyev N, Gay L, Sokol E, Hartmaier R, Deaver K, Davis S, et al.
Clin Cancer Res
. 2018 Apr;
24(13):3059-3068.
PMID: 29615459
To define the genetic landscape of advanced differentiated and anaplastic thyroid cancer (ATC) and identify genetic alterations of potential diagnostic, prognostic, and therapeutic significance. The genetic profiles of 583 advanced...
4.
Vanden Borre P, Schrock A, Anderson P, Morris 3rd J, Heilmann A, Holmes O, et al.
Oncologist
. 2017 Feb;
22(3):255-263.
PMID: 28209747
Background: Thyroid carcinoma, which is rare in pediatric patients (age 0-18 years) but more common in adolescent and young adult (AYA) patients (age 15-39 years), carries the potential for morbidity...
5.
Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim Y, Dennett K, et al.
Oncotarget
. 2016 Mar;
7(13):17194-211.
PMID: 26943572
The interaction of programmed cell death-1 and its ligand is widely studied in cancer. Monoclonal antibodies blocking these molecules have had great success but little is known about them in...
6.
Varmeh S, Vanden Borre P, Gunda V, Brauner E, Holm T, Wang Y, et al.
Surgery
. 2015 Oct;
159(1):152-62.
PMID: 26456124
Background: Investigating BRAF((V600E)) inhibitors (BRAFi) as a strategy to treat patients with aggressive thyroid tumors harboring the BRAF((V600E)) mutant currently is in progress, and drug resistance is expected to pose...
7.
Vanden Borre P, Gunda V, McFadden D, Sadow P, Varmeh S, Bernasconi M, et al.
Oncotarget
. 2014 Jul;
5(12):3996-4010.
PMID: 24994118
Anaplastic (ATC) and refractory papillary thyroid cancer (PTC) lack effective treatments. Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects in mouse models of thyroid cancer, however, neither...
8.
Vanden Borre P, McFadden D, Gunda V, Sadow P, Varmeh S, Bernasconi M, et al.
Thyroid
. 2013 Dec;
24(4):705-14.
PMID: 24295207
Background: While the development of new treatments for aggressive thyroid cancer has advanced in the last 10 years, progress has trailed headways made with other malignancies. A lack of reliable...
9.
Makkinje A, Vanden Borre P, Near R, Patel P, Lerner A
J Biol Chem
. 2012 Jun;
287(33):27703-14.
PMID: 22711540
The focal adhesion adapter protein p130(cas) regulates adhesion and growth factor-related signaling, in part through Src-mediated tyrosine phosphorylation of p130(cas). AND-34/BCAR3, one of three NSP family members, binds the p130(cas)...
10.
Vanden Borre P, Near R, Makkinje A, Mostoslavsky G, Lerner A
Cell Signal
. 2011 Jan;
23(6):1030-40.
PMID: 21262352
BCAR3 binds to the carboxy-terminus of p130Cas, a focal adhesion adapter protein. Both BCAR3 and p130Cas have been linked to resistance to anti-estrogens in breast cancer, Rac activation and cell...